Abel Costa, MD

Hematologist. Tweets are my own.

[Abel Costa, MD @anetoc]

Truly grateful and proud to be part of a defining moment at #ASH2025.

Contributing as an author to the EPCORE FL-1 trial — with simultaneous publication in @TheLancet and global regulatory impact — was a very special milestone in my academic journey. 🧵👇

[Guilherme Perini, MD @GuiperiniMD]

In his opinion, HD Mtx remains SoC in testicular lymphoma.

I agree 100%.

Let the fight begin!

[Abel Costa, MD @anetoc]

Our new review on AI in lymphoma diagnosis is out.

A realistic look at how AI can support — not replace — clinical practice.

Grateful to Marianne for the invitation and collaboration.

🔗 Link: https://t.co/4ljrzYkyt0

[OncoDaily @oncodaily]

EPCORE FL-1 Trial Shows Promising Results for Follicular Lymphoma - @anetoc

https://t.co/nbp4SSYDAC

#Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

[Abel Costa, MD @anetoc]

#ASH2025 was a meaningful milestone in my academic journey.

Being an author on 4 oral presentations and 3 posters highlights the strength of collaborative clinical research and team science.

Grateful to my mentor Eduardo Rego and the IDOR research team.

[Abel Costa, MD @anetoc]

One of the moments I was most proud of at #ASH2025 was seeing Luiza Lapolla present data from the Brazilian AML Registry, highlighting how social determinants shape AML outcomes using real-world national data.
@abhhoficial

[Abel Costa, MD @anetoc]

Glad to contribute as an author to an oral presentation at #ASH2025 on golca ± rituxi in R/R FL.

High ORR, durable responses, and manageable toxicity, even in heavily pretreated patients, supporting the role of targeted combinations in later lines.

[Abel Costa, MD @anetoc]

Grateful to contribute as an author to the TRAVERSE phase 2 study presented at #ASH2025.

A chemotherapy-free triplet regimen, AVR in treatment-naïve MCL, showed deep responses and high MRD negativity, even in biologically high-risk subgroups.

[Abel Costa, MD @anetoc]

For those who want to dive deeper, the full EPCORE FL-1 data are published in The Lancet and have already led to FDA and ANVISA approval.
https://t.co/AnJYt3C6Fz

[Abel Costa, MD @anetoc]

Truly grateful and proud to be part of a defining moment at #ASH2025.

Contributing as an author to the EPCORE FL-1 trial — with simultaneous publication in @TheLancet and global regulatory impact — was a very special milestone in my academic journey. 🧵👇

[Abel Costa, MD @anetoc]

Taken together, EPCORE FL-1 shows that epcoritamab + R² achieves deep and durable responses, delays the need for subsequent therapy, and maintains a predictable, manageable safety profile, supporting its role as a new standard of care.

[Abel Costa, MD @anetoc]

🇧🇷 Proud to represent Brazil in this milestone and to be part of a global study with strong participation from Brazilian centers, contributing to a change in standard of care.

[Abel Costa, MD @anetoc]

Why this matters:
✔️First bispecific antibody approved in combination for FL
✔️Fixed-duration, chemotherapy-free regimen
✔️Immediate impact on treatment sequencing and clinical practice

[Abel Costa, MD @anetoc]

Safety profile was manageable and predictable, with no new safety signals:

• CRS mostly grade 1–2; no grade ≥3 CRS
• No tx discontinuations due to CRS
• Neutropenia and infections were manageable
• >90% relative dose intensity maintained
Compatible with outpatient delivery.

[Abel Costa, MD @anetoc]

Despite still maturing follow-up, EPCORE FL-1 shows a statistically significant early OS signal, with separation of the curves and an HR of 0.38, favoring epcoritamab + R².

[Abel Costa, MD @anetoc]

Beyond PFS, EPCORE FL-1 showed a meaningful improvement in time to next treatment, reinforcing the durability and real-world relevance of responses.

[Abel Costa, MD @anetoc]

Key efficacy results:
• ORR: 95.7% vs 81.0%
• CR: 83% vs 50%
• 79% reduction in risk of progression or death (HR 0.21)
Benefit consistent across prespecified subgroups.

[Abel Costa, MD @anetoc]

EPCORE FL-1 design:
• Phase 3, global, randomized
• Epcoritamab + R² vs R²
• R/R FL after ≥1 prior line
• Dual primary endpoints: ORR and PFS

[Abel Costa, MD @anetoc]

Follicular lymphoma remains a chronic disease for most patients, with diminishing benefit after each line of therapy.

EPCORE FL-1 addressed a critical unmet need: a fixed-duration, chemo-free strategy capable of delivering deep and durable remissions.

[Toby Eyre @tobyeyre82]

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology https://t.co/GOEUyApbAD

[EMN @EMN_EuMMnet]

📢We are proud to announce that the EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma are now available online!
Huge thanks to Evangelos Terpos for coordinating such outstanding work! 👉https://t.co/0tLcVmnpa4 @thanosdimop @EHA_Hematology